,Canonical_Smiles,drug_name,drug_type,Label
0,C=C(C)c1ccc(OC)c(CN[C@H]2C3CCN(CC3)[C@H]2C(c2ccccc2)c2ccccc2)c1,ezlopitant_alkene_CJ_12_458,2D6-Substrate,negative
1,CCN(CC)CC(=O)Nc1c(C)cccc1C,Lidocain,HLp2-Substrate,positive
2,CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)[C@@H](CO)c1ccccc1)C2,Atropine,1A2-Inhibitor,negative
3,OCCCOc1cccc(CN2CCCCC2)c1,roxatidine_m5,2D6-Substrate,negative
4,NC(=O)CS(=O)C(c1ccccc1)c1ccccc1,Modafinil,-,negative
5,CN1CCN(CCCCN2C(=O)CN(N=Cc3ccc(-c4ccc(Cl)cc4)o3)C2=O)CC1,Azimilide,-,negative
6,COc1cc2nc(N3CCN(C(=O)[C@@H]4COc5ccccc5O4)CC3)nc(N)c2cc1OC,Doxazosin,2D6-Substrate,negative
7,COc1cc2c(c(OC)c1OC)-c1c(cc(OC)c(OC)c1OC)C[C@@H](C)[C@@H](C)C2,deoxy_schizandrin,3A4-Substrate,negative
8,Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1,Sulfamerazine,-,negative
9,COc1c2occc2cc2ccc(=O)oc12,Methoxsalen,-,negative
10,CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@H]2CC[C@H](N(C)C)[C@@H](C)O2)C=CC=CC[C@@H](C)OC(=O)C[C@H]1O,Spiramycin,3A4-Substrate,negative
11,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1,13_cis_retinoic_acid,2E1-Substrate,negative
12,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C,Cyproterone,19A-Inhibitor,negative
13,O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-],Glyceryl Trinitrate,GST-Inducer,negative
14,CCCCN(CCCC)N=O,NN_dibutyl_nitrosoamine,2E1-Substrate,negative
15,CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,Pentoxifylline,GST-Inducer,negative
16,N[Pt](N)(Cl)Cl,Cisplatin,Probable_low_affinity_copper_uptake_protein_2-Substrate,negative
17,CC(=O)C[C@H](c1ccccc1)c1c(O)c2ccccc2oc1=O,Warfarin,CP2CI-Substrate,negative
18,C[C@@H]1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1,Argatroban,HLp2-Substrate,positive
19,CN1C2CCC1CC(OC(=O)c1c[nH]c3ccccc13)C2,Tropisetron,2D6-Substrate,negative
20,CC(Cc1ccccc1)N(C)Cc1ccccc1,Benzfetamine,-,negative
21,C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,Voriconazole,-,negative
22,CC(C)C[C@@H](N(C)C)C1(c2ccc(Cl)cc2)CCC1,Sibutramine,-,negative
23,Clc1cccc(Cl)c1NC1=NCCN1,Clonidine,19A-Inducer,negative
24,CC(=O)Nc1nnc(S(N)(=O)=O)s1,Acetazolamide,-,negative
25,COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,Atazanavir,HLp2-Substrate,positive
26,O=C(C1CCCCC1)N1CC(=O)N2CCc3ccccc3[C@H]2C1,Praziquantel,HLp2-Substrate,positive
27,COc1cc2c(c3oc(=O)c4c(c13)CCC4=O)[C@@H]1C=CO[C@@H]1O2,aflatoxin_B1,1A2-Substrate,negative
28,COc1ccc2c(c1)Oc1cc(O)ccc1C21OC(=O)c2ccccc21,3_O_methyl_fluorescein,2C19-Substrate,negative
29,O=C1C(=C2Nc3ccc(S(=O)(=O)[O-])cc3C2=O)Nc2ccc(S(=O)(=O)[O-])cc21,Indigo Carmine,Coumarin_7_hydroxylase-Inhibitor,negative
30,COc1ccccc1OCCNC[C@H](O)COc1cccc2[nH]c3ccccc3c12,carvedilol_S,2D6-Substrate,negative
31,c1ccc2ncccc2c1,quinoline,2E1-Substrate,negative
32,[Cl-].[Na+],Sodium Chloride,2E1-Inducer,negative
33,Cc1onc(-c2c(F)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12,Flucloxacillin,-,negative
34,CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1,Clomifene,19A-Inhibitor,negative
35,Cc1ccccc1[C@H](OCCN(C)C)c1ccccc1,Orphenadrine (citrate),2D6-Inhibitor,negative
36,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,Cinacalcet,2D6-Substrate,negative
37,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,Chlormadinone,-,negative
38,CN1C(=O)C[C@@](C)(c2ccccc2)C1=O,Mesuximide,2C19-Inhibitor,negative
39,CC(=O)N[C@H](CS)C(=O)O,Acetylcysteine,Multidrug_resistance_protein_1-Inducer,negative
40,O=c1[nH]c(=O)n(C2CCCO2)cc1F,tegafur,2E1-Substrate,negative
41,O=C1CN=C(c2ccccn2)c2cc(Br)ccc2N1,Bromazepam,2E1-Inhibitor,negative
42,O=Cc1c2ccccc2cc2ccccc12,9_anthraldehyde,2E1-Substrate,negative
43,O=C1C(CCS(=O)c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1,Sulfinpyrazone,-,negative
44,c1ccc2[nH]c(-c3cscn3)nc2c1,Tiabendazole,-,negative
45,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O,Diflunisal,UGT-Substrate,negative
46,N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H]1CSSCCC(=O)N[C@H](Cc2ccc(O)cc2)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,Desmopressin,Solute_carrier_family_12_member_1-Inducer,negative
47,CCCCCCCCCCCCCC(=O)O,myristic_acid,2E1-Substrate,negative
48,Cc1cc(Cl)c(S(N)(=O)=O)cc1S(N)(=O)=O,Disulfamide,-,negative
49,O=[N+]([O-])OC1COC2C(O[N+](=O)[O-])COC12,Isosorbide dinitrate,-,negative
50,Clc1ccc(CON=C(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,Oxiconazole,-,negative
51,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,Risperidone,HLp2-Substrate,positive
52,COc1ccc(-c2cc(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]5O)[C@H](O)[C@H](O)[C@H]4O)cc3o2)cc1O,Diosmin,Methyltransferase-Inhibitor,negative
53,Nc1nc2c(ncn2COCCO)c(=O)[nH]1,Aciclovir,Canalicular_multispecific_organic_anion_transporter_1-Substrate,negative
54,Cc1cc2ccccc2c2ccc3ccccc3c12,5_methylchrysene,2E1-Substrate,negative
55,CC(N)Cc1ccc2c(c1)OCO2,MDA_tenamfetamine,2D6-Substrate,negative
56,Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,Azathioprine,Methyltransferase-Substrate,negative
57,COC(=O)Nc1nc2cc(C(=O)c3ccccc3)ccc2[nH]1,Mebendazole,-,negative
58,O=C(CO)NCCCOc1cccc(CN2CCCCC2)c1,Roxatidine,2D6-Substrate,negative
59,CCCCc1nc(Cl)c(C=O)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,losartan_carboxaldehyde_EXP_3179,2C9-Substrate,negative
60,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,Doxycycline,-,negative
61,CC(C)(C)NC[C@H](O)COc1cccc2c1CCC(=O)N2,Carteolol,2D6-Inhibitor,negative
62,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(c2ccccc2)c2ccccc2)[C@H]1c1cccc([N+](=O)[O-])c1,Lercanidipine,HLp2-Substrate,positive
63,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,Hydrocortisone,HLp2-Substrate,positive
64,COc1cc2nc(N(C)CCCNC(=O)[C@H]3CCCO3)nc(N)c2cc1OC,Alfuzosin,3A4-Substrate,negative
65,C[C@@H]1O[C@@]2(CS1)CN1CCC2CC1,SNI_2011_R_R,2D6-Substrate,negative
66,CCc1cccc2c3c([nH]c12)[C@@](CC)(CC(=O)O)OCC3,etodolac_R,2C9-Substrate,negative
67,Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,Adenosine,Sodiumbile_acid_cotransporter-Inducer,negative
68,N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O,Levodopa,Methyltransferase-Substrate,negative
69,COc1ccc(OC)c([C@H](O)CNC(=O)CN)c1,Midodrine,2D6-Inhibitor,negative
70,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)C1=O,9_alpha_fluoro_androstadienedione,3A4-Substrate,negative
71,FC(F)(F)C(Cl)Br,halothane,2E1-Substrate,negative
72,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=C[C@H](O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,Cortisone,HLp2-Substrate,positive
73,Cc1ccc(S(=O)(=O)N(C)c2ccnn2-c2ccccc2)cc1,DMZ,2C19-Substrate,negative
74,CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,Budesonide,SUL-Substrate,negative
75,NC[C@H](O)c1ccc(O)cc1,Octopamine,HLp2-Substrate,positive
76,C[C@H](CN(C)C)CN1c2ccccc2CCc2ccccc21,Trimipramine,2D6-Substrate,negative
77,CCCCCCCC/C=C\CCCCCCCC(=O)O,oleic_acid,2E1-Substrate,negative
78,COC1=C[C@@H](C)[C@@H]2C[C@@H]3OC(=O)C[C@H]4C(C)=C(OC)C(=O)[C@H]([C@@]2(C)C1=O)[C@]34C,Quassia,1A1-Inhibitor,negative
79,CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1,Clofibrate,4A11-Substrate,negative
80,CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1,NE_100,2D6-Substrate,negative
81,CC(C)(C)NCC(O)COc1ccccc1C#N,Bunitrolol,2D6-Substrate,negative
82,COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@@H]2CCCN(Cc3ccccc3)C2)[C@H]1c1cccc([N+](=O)[O-])c1,Benidipine,2D6-Inhibitor,negative
83,CCN(CC)C(=O)c1cccc(C)c1,Diethyltoluamide,HLp2-Substrate,positive
84,C[C@H](S)C(=O)NCC(=O)O,Tiopronin,2E1-Inhibitor,negative
85,Nc1cc(N2CCCCC2)nc(N)[n+]1[O-],Minoxidil,SUL-Substrate,negative
86,CC(C)(CO)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,w_OH_finasteride,3A4-Substrate,negative
87,O=C(CCCN1CCC(O)(c2cccc(C(F)(F)F)c2)CC1)c1ccc(F)cc1,Trifluperidol,2D6-Substrate,negative
88,C[C@H](N)Cc1ccccc1,Dexamfetamine,2D6-Inhibitor,negative
89,COc1c(N2CCN[C@@H](C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,Gatifloxacin,-,negative
90,CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,Paclitaxel,HLp2-Substrate,positive
91,CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,Lisuride,2D6-Substrate,negative
92,O=C(O)c1ccc(OCCn2ccnc2)cc1,Dazoxiben,-,negative
93,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1,Mirtazapine,2D6-Inhibitor,negative
94,O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,thalidomide,2C19-Substrate,negative
95,C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@H]3CC[C@@H](C(=O)N(C)C)N3)[C@H](C)[C@H]12,Meropenem,Solute_carrier_family_22_member_6-Substrate,negative
96,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@H]2O[C@@H](C)C[C@@H](N(C)C)[C@@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,Erythromycin,HLp2-Substrate,positive
97,O=C(Cn1c(=O)sc2ccc(Cl)cc21)N1CCN(CCO)CC1,Tiaramide,-,negative
98,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,Medroxyprogesterone,-,negative
99,OC(CNCC(F)(F)F)COc1cccc2ccccc12,N_trifluoro_ethyl_desisopropyl_propranolol,2D6-Substrate,negative
100,CC[C@H](C)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CO)NC(=O)[C@H]1CCCN1C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN)[C@H](C)CC)C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O)c1ccc(OS(=O)(=O)O)cc1,Pancreozymin (cholecystokinin),Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
101,O=C1CN(N=Cc2ccc([N+](=O)[O-])o2)C(=O)N1,Nitrofurantoin,ATP_binding_cassette_sub_family_G_member_2-Substrate,negative
102,COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(=O)O)cc1,TR_14035,2C9-Substrate,negative
103,OCCOCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,Hydroxyzine,2D6-Inhibitor,negative
104,CCCCOC(=O)c1ccccc1C(=O)OCCCC,Dibutylphthalate,19A-Inducer,negative
105,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,Captopril,Methyltransferase-Substrate,negative
106,NN=c1[nH]ncc2ccccc12,Hydralazine,Methyltransferase-Inducer,negative
107,COc1ccc(C(=O)Nc2ccccc2[C@H](C)CN2CCCCC2)cc1,Encainide,2D6-Substrate,negative
108,Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,Paroxetine,2D6-Inhibitor,negative
109,CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1,Roquinimex,-,negative
110,Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1,Thiamine (vit B1),P450_HP-Inducer,negative
111,O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,Cilostazol,2D6-Substrate,negative
112,NNC(=O)c1ccncc1,Isoniazid,2E1-Inducer,negative
113,O=C(O)COc1ccc(C(=O)c2cccs2)cc1,suprofen_desmethyl,2C9-Substrate,negative
114,CN1C(=O)[C@](C)(C2=CCCCC2)C(=O)N=C1O,Hexobarbital,-,negative
115,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@](C)(F)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,Flurithromycin,-,negative
116,CN[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H]([C@@H](C)NC)CC[C@@H]3N)[C@@H]2O)OC[C@]1(C)O,Gentamicin,Canalicular_multispecific_organic_anion_transporter_1-Inducer,negative
117,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,Methotrexate,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
118,C[C@H]1O[C@@H]1P(=O)(O)O,Fosfomycin,GST-Substrate,negative
119,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,Rutoside,2D6-Inhibitor,negative
120,O=[P@]1(NCCCl)OCCCN1CCCl,Ifosfamide,HLp2-Substrate,positive
121,CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC,Remoxipride,2D6-Substrate,negative
122,Cc1cccc(CN2CCN([C@@H](c3ccccc3)c3ccc(Cl)cc3)CC2)c1,Meclozin,1A2-Inhibitor,negative
123,COC(=O)Nc1nc2cc(Sc3ccccc3)ccc2[nH]1,Fenbendazole,1A2-Inducer,negative
124,C[C@H](CCC(=O)O)[C@@H]1CC[C@H]2[C@H]3[C@H](CC[C@]12C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O,chenodeoxycholic_acid,3A4-Substrate,negative
125,COc1ccc2ccc(=O)oc2c1,7_methoxy_coumarin,2E1-Substrate,negative
126,CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1,Proguanil,2E1-Substrate,negative
127,O=C(O)CC(O)(CC(=O)O)C(=O)[O-],Sodium Citrate,SUL-Inhibitor,negative
128,COc1ccc(CCN(C)CCC[C@](C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,verapamil_R,2C8-Substrate,negative
129,Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1,Ambroxol,-,negative
130,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,Hydromorphone,2D6-Substrate,negative
131,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1,Oxaprozin,2C9-Substrate,negative
132,CC(C=CC1=C(C)CCCC1(C)C)=C/C=C/C(C)=C/C(=O)O,Alitretinoin,1A2-Inhibitor,negative
133,CCN(CC)CCOCCOC(=O)C1(c2ccccc2)CCCC1,Pentoxyverine,2D6-Substrate,negative
134,Cn1cnc2c1c(=O)[nH]c(=O)n2C,Theobromine,2E1-Substrate,negative
135,CC(C)=O,Acetone,-,negative
136,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1,Tamsulosin,2D6-Substrate,negative
137,COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314,Hydrocodone,2D6-Substrate,negative
138,COc1ccc(OC(F)(F)F)cc1CN[C@H]1CCCN[C@H]1c1ccccc1,cp_122_721,2D6-Substrate,negative
139,CC[C@]12CCCN3CCc4c(n(c5ccccc45)[C@@](O)(C(=O)OC)C1)[C@@H]32,Vincamine,2E1-Substrate,negative
140,NC[C@@H](O)c1ccc(O)c(O)c1,Norepinephrine,19A-Inhibitor,negative
141,COc1ccc([N+](=O)[O-])cc1,4_nitroanisole,2E1-Substrate,negative
142,Cc1cccc(C)c1NC(=O)CN1CCCC1=O,Nefiracetam,-,negative
143,CC(=O)O,Acetic Acid,2E1-Substrate,negative
144,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O,Amodiaquine,2D6-Inhibitor,negative
145,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC=Cc2ccccc2)[C@H]1c1cccc([N+](=O)[O-])c1,Cilnidipine,-,negative
146,CC(N)C(=O)c1ccccc1,Cathinone,-,negative
147,CCN(CC)C(=O)SC,DETC_Me,2E1-Substrate,negative
148,CO[C@H]1C=CO[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,Rifaximin,3A4-Inducer,negative
149,Cc1cc(CCCOc2c(C)cc(-c3noc(C(F)(F)F)n3)cc2C)on1,Pleconaril,P450_HFLA-Inducer,negative
150,CC(C)(C)c1cc(CC2SCNC2=O)cc(C(C)(C)C)c1O,Tazofelone,-,negative
151,COc1ccc2c3c1OC1C(O)C=CC4C(C2)NCCC341,Norcodeine,2D6-Substrate,negative
152,CC1(C)Cc2c(-c3ccccc3)c(-c3ccc(Cl)cc3)c(CC(=O)O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)n2C1,licofelone_M1,2C8-Substrate,negative
153,CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,Trifluoperazine,-,negative
154,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O,Indinavir,HLp2-Substrate,positive
155,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,Spironolactone,-,negative
156,CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc21)OCOC(=O)C(C)(C)C,Adefovir Dipivoxil,2C9-Inhibitor,negative
157,CCOP(=S)(OCC)Oc1ccc([N+](=O)[O-])cc1,parathion,2E1-Substrate,negative
158,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,Gefitinib,2D6-Inhibitor,negative
159,CN1C2CC[C@H]1CC(OC(=O)c1c[nH]c3ccccc13)C2,tropisetron,2D6-Substrate,negative
160,CCCCN(C)N=O,NN_methyl_butyl_nitrosoamine,2E1-Substrate,negative
161,Cc1cccc(Nc2ccccc2C(=O)O)c1C,Mefenamic acid,-,negative
162,CS(=O)(=O)Nc1ccc([N+](=O)[O-])cc1Oc1ccccc1,Nimesulide,2C9-Inhibitor,negative
163,CCC[C@@H](C)C1(CC)C(=O)NC(=O)NC1=O,Pentobarbital,-,negative
164,CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl,Etizolam,2C19-Substrate,negative
165,CN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1,Mizolastine,2E1-Inhibitor,negative
166,COc1ccc2cc(CCC(C)=O)ccc2c1,nabumetone,2E1-Substrate,negative
167,ClC(Cl)Cl,Chloroform,2E1-Substrate,negative
168,C/C=C1/C[C@@H](C)[C@@](C)(O)C(=O)OCC2=CCN3CC[C@@H](OC1=O)[C@@H]23,senecionine,3A4-Substrate,negative
169,C[C@@H](N)Cc1ccccc1,Amfetamine,2D6-Inhibitor,negative
170,CSc1ccc2c(c1)N(CC[C@H]1CCCCN1C)c1ccccc1S2,thioridazine_R,2E1-Substrate,negative
171,CN(C)c1ccc([C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,onapristone,3A4-Substrate,negative
172,COc1ccc(OC)c([C@@H](O)[C@@H](C)N)c1,Methoxamine,Solute_carrier_family_12_member_2-Inducer,negative
173,O=[P@@]1(N(CCCl)CCCl)NCCCO1,Cyclophosphamide,CP2CI-Substrate,negative
174,Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C,Sulfamoxole,-,negative
175,NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O,Chlorothiazide,Solute_carrier_family_22_member_8-Substrate,negative
176,COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)[C@H]1c1cccc([N+](=O)[O-])c1,Nilvadipine,2E1-Substrate,negative
177,CCn1nnc(C2=CCCN(C)C2)n1,LU_2509,2D6-Substrate,negative
178,CC(C)(C(=O)O)c1ccc([C@@H](O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,Fexofenadine,2D6-Inhibitor,negative
179,Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1,Lumiracoxib,Solute_carrier_family_22_member_6-Inhibitor,negative
180,CCCCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_4,3A4-Substrate,negative
181,CN(C)CCC=C1c2ccccc2CCc2ccccc21,Amitriptyline,HLp2-Substrate,positive
182,CN(C)CCO[C@@](C)(c1ccccc1)c1ccccn1,Doxylamin,P450_HFLA-Inducer,negative
183,O=C1C=C2CN(Cc3ccccc3Cl)CCC2S1,2_oxo_ticlopidine,2D6-Substrate,negative
184,CCCCCCCC(C)O,2_nonanol,2E1-Substrate,negative
185,C1CCC(C(C[C@H]2CCCCN2)C2CCCCC2)CC1,Perhexiline,2D6-Substrate,negative
186,O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O,Sulfasalazine,HLp2-Substrate,positive
187,CCCCCCOc1ccc2ccc(=O)oc2c1,7_hexoxy_coumarin,3A4-Substrate,negative
188,COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC,Sulfadoxine,-,negative
189,CNCC[C@@H](Oc1ccccc1C)c1ccccc1,Atomoxetine,2D6-Inhibitor,negative
190,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,Haloperidol,HLp2-Substrate,positive
191,C/C=C/C,trans_2_butene,2E1-Substrate,negative
192,CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C,Tenofovir Disoproxil,2E1-Inhibitor,negative
193,O=S(=O)([O-])[O-],Sodium Sulfate,P450_HP-Inducer,negative
194,C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)C)C[C@@H](O)C[C@@H]1O,1_alpha_hydroxy_vitamin_D2,3A4-Substrate,negative
195,Cn1c(N)nc2ncc(-c3ccccc3)cc21,2_amino_1_methyl_6_phenylimidazo_4_5_b_pyridine,1A2-Substrate,negative
196,CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,taxol,2C8-Substrate,negative
197,CON=C(C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1,Ceftriaxone,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
198,CC[C@H](C)[C@H]1NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(N)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@@H](CCC(N)=O)NC1=O,Vasopressin,Solute_carrier_family_12_member_1-Inducer,negative
199,Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,Nevirapine,2D6-Substrate,negative
200,CCOC(=O)C(CCc1ccccc1)NC(C)C(=O)N(CC(=O)O)C1Cc2ccccc2C1,Delapril,-,negative
201,CO[C@@H](CNC(=O)c1ccccc1OCC(=O)[O-])C[Hg]O,Sodium Salicylate,2E1-Inducer,negative
202,CNC(=S)Oc1cc(C)c(SC)c(C)c1,methiocarb,2D6-Substrate,negative
203,Cc1nccn1C[C@@H]1CCc2c(c3ccccc3n2C)C1=O,ondansetron,2D6-Substrate,negative
204,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,Fentanyl,HLp2-Substrate,positive
205,CC[C@@]1(c2ccccc2)C(=O)NC(=O)N(C)C1=O,Methylphenobarbital,-,negative
206,O=C(O)COc1ccc(C(=O)c2ccsc2)c(Cl)c1Cl,tienilic_acid_deriv_3_isomer,2C9-Substrate,negative
207,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,Betamethason,19A-Inducer,negative
208,CNCCCC1c2ccccc2C=Cc2ccccc21,Protriptyline,2D6-Substrate,negative
209,CC(C)O,Isopropanol,2E1-Inducer,negative
210,FC(F)OC(F)(F)C(F)Cl,enflurane,2E1-Substrate,negative
211,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,Dasatinib,UGT-Inhibitor,negative
212,S=P(N1CC1)(N1CC1)N1CC1,Thiotepa,GST-Substrate,negative
213,Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1,Sulfadimidine,-,negative
214,CC(C)N1CCN(c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,Terconazole,Sterol_14_alpha_demethylase_Lanosterol_14_alpha_demethylase-Inhibitor,negative
215,O=C(OC1CC2CCC(C1)[N+]21CCCC1)C(O)(c1ccccc1)c1ccccc1.[Cl-],Trospium chloride,-,negative
216,Cc1nnc2n1-c1sc(Br)cc1C(c1ccccc1Cl)=NC2,Brotizolam,-,negative
217,C[C@H](C(=O)O)c1ccc(C(=O)c2cccs2)cc1,Suprofen,-,negative
218,CN(C)c1ccc(C2CC3(C)C(CCC3(O)CCCO)C3CCC4=CC(=O)CCC4=C23)cc1,Onapristone,-,negative
219,C=C1CC[C@H](O)CC1=CC=C1CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)C=C[C@H](C)C(C)C,Ergocalciferol,Arachidonic_acid_epoxygenase-Substrate,negative
220,CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O,Nilutamide,-,negative
221,Fc1ccccc1C1=NCC(=S)N(CC(F)(F)F)c2ccc(Cl)cc21,Quazepam,2C19-Substrate,negative
222,CC(=O)O[C@H](CC(=O)[O-])C[N+](C)(C)C,Acetylcarnitine,Solute_carrier_family_22_member_5-Substrate,negative
223,COc1ccccc1OCCNC[C@@H](O)COc1cccc2[nH]c3ccccc3c12,Carvedilol,2E1-Substrate,negative
224,CN1CCCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,Homochlorcyclizine,-,negative
225,C=CC[C@@H]1C=C(C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](C(C)=C[C@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,Tacrolimus,HLp2-Substrate,positive
226,COc1cc2c(cc1OC)C(=O)[C@H](CC1CCN(Cc3ccccc3)CC1)C2,Donepezil,2D6-Substrate,negative
227,C#CCNC1CCc2ccccc21,Rasagiline,1A2-Substrate,negative
228,O=C1CN(N=Cc2ccc(-c3ccc([N+](=O)[O-])cc3)o2)C(=O)N1,Dantrolene,-,negative
